229 related articles for article (PubMed ID: 11161399)
1. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring markers of bone turnover in multiple myeloma].
Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
[TBL] [Abstract][Full Text] [Related]
3. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
4. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.
Seibel MJ; Woitge HW; Pecherstorfer M; Karmatschek M; Horn E; Ludwig H; Armbruster FP; Ziegler R
J Clin Endocrinol Metab; 1996 Sep; 81(9):3289-94. PubMed ID: 8784085
[TBL] [Abstract][Full Text] [Related]
5. Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM).
Mejjad O; Le Loët X; Basuyau JP; Ménard JF; Jego P; Grisot C; Daragon A; Grosbois B; Euller-Ziegler L; Monconduit M
Eur J Haematol; 1996; 56(1-2):30-4. PubMed ID: 8599990
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M
Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis.
Woitge HW; Horn E; Keck AV; Auler B; Seibel MJ; Pecherstorfer M
Clin Chem; 2001 Apr; 47(4):686-93. PubMed ID: 11274019
[TBL] [Abstract][Full Text] [Related]
8. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
Samani KK; Brazier M; Mathiot C; Kamel S; Jamart J; Jaubert J; Blanc M; Azaïs I; Facon T; Leleu X
Ann Hematol; 2005 Jan; 84(1):19-24. PubMed ID: 15338198
[TBL] [Abstract][Full Text] [Related]
10. Bone sialoprotein is a specific biochemical marker of bone metabolism in postmenopausal women: a randomized 1-year study.
Störk S; Störk C; Angerer P; Kothny W; Schmitt P; Wehr U; von Schacky C; Rambeck W
Osteoporos Int; 2000; 11(9):790-6. PubMed ID: 11148806
[TBL] [Abstract][Full Text] [Related]
11. Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover.
Scillitani A; Dicembrino F; Chiodini I; Minisola S; Fusilli S; Di Giorgio A; Garrubba M; D'Aloiso L; Frusciante V; Torlontano M; Modoni S; Trischitta V; Trischitta V; Carnevale V
Osteoporos Int; 2002 Oct; 13(10):829-34. PubMed ID: 12378373
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
[TBL] [Abstract][Full Text] [Related]
13. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
14. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
15. Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.
Greco C; Alvino S; Del Monte G; Venturo I; Lopez M
J Exp Clin Cancer Res; 2003 Dec; 22(4):607-12. PubMed ID: 15053303
[TBL] [Abstract][Full Text] [Related]
16. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
18. Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients.
Zdzisińska B; Wejksza K; Walter-Croneck A; Turski WA; Kandefer-Szerszeń M
Leuk Res; 2010 Jan; 34(1):38-45. PubMed ID: 19596432
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of bone turnover in diagnosis of myeloma bone disease.
Dizdar O; Barista I; Kalyoncu U; Karadag O; Hascelik G; Cila A; Pinar A; Celik I; Kars A; Tekuzman G
Am J Hematol; 2007 Mar; 82(3):185-91. PubMed ID: 17022050
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
